摘要
目的:评定HPLC-MS/MS测定人血浆中卡马西平(CBZ)浓度的不确定度。方法:分析HPLC-MS/MS法测定人血浆中CBZ浓度的不确定度来源,计算并进行合成和扩展。结果:人血浆中低浓度(7.46 ng·ml^(-1))和高浓度(745 ng·ml^(-1))CBZ的扩展不确定度分别为0.410 ng·ml^(-1)和33.400 ng·ml^(-1)(P=95%,k=2)。结论:HPLC-MS/MS法测定人血浆中CBZ浓度的不确定度在低浓度时主要由回收率、生物样品配制和基质效应引入,在高浓度时主要由生物样品配制和重复性引入。
Objective： To evaluate the uncertainty in carbamazepine（ CBZ） determination in human plasma by HPLC-MS / MS.Methods： The whole process of CBZ determination was analyzed and the uncertainty sources were established,and then the uncertainty was evaluated and combined,and the expanded uncertainty was also calculated. Results： The expanded uncertainty of CBZ with low（7. 46 ng·ml^（-1）） and high（745 ng·ml^（-1）） levels was 0. 410 ng·ml^（-1） and 33. 400 ng·ml^（-1）,respectively（P = 95%,k = 2）.Conclusion： The uncertainty in CBZ determination in human plasma by HPLC-MS / MS is mainly caused by recovery,sample preparation and matrix effect for low concentration,and by sample preparation and repeatability for high concentration.
出处
《中国药师》
CAS
2016年第3期419-423,共5页
China Pharmacist
基金
国家自然科学基金项目(编号:81301118)
多肽及小分子药物北京市重点实验室开放课题(编号:2014DTYW03)
